Actively Recruiting
Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas
Led by Asan Medical Center · Updated on 2024-05-14
100
Participants Needed
1
Research Sites
307 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.
CONDITIONS
Official Title
Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have radiologically and histologically confirmed diagnosis of newly diagnosed glioblastoma
- Patients must have measurable disease, defined as evident tumors with gadolinium enhancement on MRI that is measurable in at least one diameter
- Life expectancy of greater than 3 months
- Patients scheduled for standard therapy (6 weeks radiation treatment (~ 60 Gy) plus temozolomide 75 mg/m2 during 6 week RT, and followed by routine monthly temozolomide therapy)
- Ability to understand and the willingness to sign a written informed consent document; all patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines
You will not qualify if you...
- Patients who underwent complete resection
- Patients with no evidence of measurable disease after surgery
- Patients who have had chemotherapy or radiotherapy
- Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, electronic infusion pumps, etc)
- Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
- Patients with baseline MR images that exhibit enough signal degradation from surgical artifacts making data uninterpretable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asan Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
H
Ho Sung Kim, MD, PhD
CONTACT
J
Ji Eun Park, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here